• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用简化的分段指数方法改进癌症研究中的生存模型。

Improved survival modeling in cancer research using a reduced piecewise exponential approach.

作者信息

Han Gang, Schell Michael J, Kim Jongphil

机构信息

Department of Biostatistics, Yale University School of Public Health, 60 College Street, New Haven, CT 06520, U.S.A.

出版信息

Stat Med. 2014 Jan 15;33(1):59-73. doi: 10.1002/sim.5915. Epub 2013 Jul 30.

DOI:10.1002/sim.5915
PMID:23900779
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3913785/
Abstract

Statistical models for survival data are typically nonparametric, for example, the Kaplan-Meier curve. Parametric survival modeling, such as exponential modeling, however, can reveal additional insights and be more efficient than nonparametric alternatives. A major constraint of the existing exponential models is the lack of flexibility due to distribution assumptions. A flexible and parsimonious piecewise exponential model is presented to best use the exponential models for arbitrary survival data. This model identifies shifts in the failure rate over time based on an exact likelihood ratio test, a backward elimination procedure, and an optional presumed order restriction on the hazard rate. Such modeling provides a descriptive tool in understanding the patient survival in addition to the Kaplan-Meier curve. This approach is compared with alternative survival models in simulation examples and illustrated in clinical studies.

摘要

生存数据的统计模型通常是非参数的,例如Kaplan-Meier曲线。然而,参数生存建模,如指数建模,可以揭示更多见解,并且比非参数方法更有效。现有指数模型的一个主要限制是由于分布假设而缺乏灵活性。提出了一种灵活且简约的分段指数模型,以最佳地将指数模型用于任意生存数据。该模型基于精确似然比检验、向后消除程序以及对危险率的可选假定顺序限制来识别随时间变化的失效率变化。除了Kaplan-Meier曲线之外,这种建模还提供了一种理解患者生存情况的描述工具。在模拟示例中将该方法与其他生存模型进行了比较,并在临床研究中进行了说明。

相似文献

1
Improved survival modeling in cancer research using a reduced piecewise exponential approach.使用简化的分段指数方法改进癌症研究中的生存模型。
Stat Med. 2014 Jan 15;33(1):59-73. doi: 10.1002/sim.5915. Epub 2013 Jul 30.
2
Model building in nonproportional hazard regression.非比例风险回归中的模型构建
Stat Med. 2013 Dec 30;32(30):5301-14. doi: 10.1002/sim.5961. Epub 2013 Sep 6.
3
Confidence intervals for median survival times under a piecewise exponential model with proportional hazards covariate effects.具有比例风险协变量效应的分段指数模型下中位生存时间的置信区间。
Stat Med. 1996 Jan 30;15(2):171-82. doi: 10.1002/(SICI)1097-0258(19960130)15:2<171::AID-SIM146>3.0.CO;2-U.
4
Design and monitoring of survival trials based on restricted mean survival times.基于受限平均生存时间的生存试验设计与监测。
Clin Trials. 2019 Dec;16(6):616-625. doi: 10.1177/1740774519871447. Epub 2019 Aug 26.
5
A Weibull multi-state model for the dependence of progression-free survival and overall survival.一种用于无进展生存期和总生存期相关性的威布尔多状态模型。
Stat Med. 2015 Jul 30;34(17):2497-513. doi: 10.1002/sim.6501. Epub 2015 Apr 10.
6
A flexible parametric survival model for fitting time to event data in clinical trials.一种用于拟合临床试验中事件发生时间数据的灵活参数生存模型。
Pharm Stat. 2019 Oct;18(5):555-567. doi: 10.1002/pst.1947. Epub 2019 Apr 29.
7
On a new piecewise regression model with cure rate: Diagnostics and application to medical data.具有治愈率的分段回归模型:诊断与医学数据应用。
Stat Med. 2021 Dec 20;40(29):6723-6742. doi: 10.1002/sim.9208. Epub 2021 Sep 28.
8
Adjusting for overdispersion in piecewise exponential regression models to estimate excess mortality rate in population-based research.在基于人群的研究中,调整分段指数回归模型中的过度离散以估计超额死亡率。
BMC Med Res Methodol. 2016 Oct 1;16(1):129. doi: 10.1186/s12874-016-0234-z.
9
Weibull prediction of event times in clinical trials.临床试验中事件时间的威布尔预测。
Pharm Stat. 2008 Apr-Jun;7(2):107-20. doi: 10.1002/pst.271.
10
Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis.个体患者数据荟萃分析中估计受限平均生存时间差异的方法的偏倚和精度。
BMC Med Res Methodol. 2016 Mar 29;16:37. doi: 10.1186/s12874-016-0137-z.

引用本文的文献

1
Recurrence Incidence and Optimal Surveillance After Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Mucinous Appendix Cancer.黏液性阑尾癌行完全减瘤手术及热灌注化疗后的复发率及最佳监测
Ann Surg Oncol. 2025 Sep 9. doi: 10.1245/s10434-025-18203-x.
2
Imputation of Missing Data for Time-to-Event Endpoints Using Retrieved Dropouts.利用追回的脱落数据对事件时间终点缺失数据进行插补。
Ther Innov Regul Sci. 2024 Jan;58(1):114-126. doi: 10.1007/s43441-023-00575-5. Epub 2023 Oct 7.
3
Lipid-Based Factors: A Promising New Biomarker for Predicting Prognosis and Conditional Survival Probability in Hepatocellular Carcinoma.

本文引用的文献

1
Comparing Two Exponential Distributions Using the Exact Likelihood Ratio Test.使用精确似然比检验比较两个指数分布
Stat Biopharm Res. 2012 Oct 1;4(4):348-356. doi: 10.1080/19466315.2012.698945.
2
Detecting multiple change points in piecewise constant hazard functions.检测分段常数风险函数中的多个变化点。
J Appl Stat. 2011 Jan 1;38(11):2523-2532. doi: 10.1080/02664763.2011.559209. Epub 2011 Mar 9.
3
Connexin 43 is a potential prognostic biomarker for ewing sarcoma/primitive neuroectodermal tumor.连接蛋白43是尤因肉瘤/原始神经外胚层肿瘤的一种潜在预后生物标志物。
基于脂质的因素:一种用于预测肝细胞癌预后和条件生存概率的有前景的新生物标志物。
J Hepatocell Carcinoma. 2022 Aug 26;9:869-883. doi: 10.2147/JHC.S360871. eCollection 2022.
4
Bridged parametric survival models: General paradigm and speed improvements.桥接参数生存模型:一般范例与速度改进。
Comput Methods Programs Biomed. 2021 Jul;206:106115. doi: 10.1016/j.cmpb.2021.106115. Epub 2021 Apr 28.
5
Conditional survival and hazards of death for peripheral T-cell lymphomas.外周 T 细胞淋巴瘤的条件生存和死亡风险。
Aging (Albany NY). 2021 Mar 26;13(7):10225-10239. doi: 10.18632/aging.202782.
6
Radiological assessment schedule for high-grade glioma patients during the surveillance period using parametric modeling.使用参数建模对高级别胶质瘤患者在监测期进行的放射学评估时间表。
Neuro Oncol. 2021 May 5;23(5):837-847. doi: 10.1093/neuonc/noaa250.
7
Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial.氟维司群单药或联合硼替佐米用于对芳香化酶抑制剂耐药的激素受体阳性转移性乳腺癌的随机II期试验:一项纽约癌症联盟试验
NPJ Breast Cancer. 2016 Dec 14;2:16037. doi: 10.1038/npjbcancer.2016.37. eCollection 2016.
8
End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma.免疫肿瘤学试验的终点和统计学考虑因素:对多发性骨髓瘤的影响。
Future Oncol. 2017 Jun;13(13):1181-1193. doi: 10.2217/fon-2016-0504. Epub 2017 Apr 11.
9
Testing violations of the exponential assumption in cancer clinical trials with survival endpoints.在以生存为终点的癌症临床试验中检验指数假设的违背情况。
Biometrics. 2017 Jun;73(2):687-695. doi: 10.1111/biom.12590. Epub 2016 Sep 26.
10
Identifying change points in a covariate effect on time-to-event analysis with reduced isotonic regression.使用简化等距回归在事件发生时间分析中识别协变量效应的变化点。
PLoS One. 2014 Dec 4;9(12):e113948. doi: 10.1371/journal.pone.0113948. eCollection 2014.
Sarcoma. 2011;2011:971050. doi: 10.1155/2011/971050. Epub 2011 May 8.
4
Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma.马来酸舒尼替尼的 II 期研究,一种多靶点酪氨酸激酶抑制剂,用于治疗复发性或难治性软组织肉瘤患者。重点关注三种常见的组织学类型:平滑肌肉瘤、脂肪肉瘤和恶性纤维组织细胞瘤。
Int J Cancer. 2011 Oct 15;129(8):1963-9. doi: 10.1002/ijc.25843. Epub 2011 Mar 25.
5
Improved endpoints for cancer immunotherapy trials.癌症免疫疗法试验的改善终点。
J Natl Cancer Inst. 2010 Sep 22;102(18):1388-97. doi: 10.1093/jnci/djq310. Epub 2010 Sep 8.
6
The hazards of endpoints.终点的风险。
J Natl Cancer Inst. 2010 Sep 22;102(18):1376-7. doi: 10.1093/jnci/djq334. Epub 2010 Sep 8.
7
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.评估癌症治疗药物的 II 期临床试验设计:美国国家癌症研究所试验药物指导委员会临床试验设计工作组的共识建议。
Clin Cancer Res. 2010 Mar 15;16(6):1764-9. doi: 10.1158/1078-0432.CCR-09-3287. Epub 2010 Mar 9.
8
Estimating the grid of time-points for the piecewise exponential model.估计分段指数模型的时间点网格。
Lifetime Data Anal. 2008 Sep;14(3):333-56. doi: 10.1007/s10985-008-9086-0. Epub 2008 May 9.
9
Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older.多西他赛与吉非替尼一线治疗70岁及以上晚期非小细胞肺癌(NSCLC)患者的2期试验。
Cancer. 2008 May 1;112(9):2021-9. doi: 10.1002/cncr.23360.
10
Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).小细胞肺癌的管理:美国胸科医师学会循证临床实践指南(第2版)
Chest. 2007 Sep;132(3 Suppl):324S-339S. doi: 10.1378/chest.07-1385.